Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

Janaushadhi Kendra Owners Honoured on 8th Janaushadhi Diwas

March 07, 2026 5 min read Polity & Governance GS Paper 2 (Social Justice Health Government Schemes)
On This Page ▼

What Happened

  • The 8th Jan Aushadhi Diwas (March 7, 2026) was observed nationwide, with Janaushadhi Kendra operators honoured for their role in making affordable generic medicines accessible across India.
  • The Pharmaceuticals and Medical Devices Bureau of India (PMBI) organised over 250 health camps from March 1-5, 2026, offering free blood tests, blood pressure checks, doctor consultations, and free medicines.
  • The 2026 theme — "Jan Aushadhi Sasti Bhi, Bharosemand Bhi — Sehat ki Baat, Bachat ke Saath" — emphasises that generic medicines are not just cheap but also trustworthy, addressing the persistent perception gap between branded and generic drugs.
  • The scheme now operates more than 18,000 Jan Aushadhi Kendras (JAKs) across the country, with an ambitious target of expanding to 25,000 Kendras by March 31, 2027.

Static Topic Bridges

Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP): Architecture and Impact

PMBJP was launched by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, to provide quality generic medicines at affordable prices through dedicated outlets called Pradhan Mantri Bhartiya Jan Aushadhi Kendras (PMBJAKs). The scheme builds on an earlier 2008 initiative and was significantly revamped and rebranded as PMBJP in 2015. Generic medicines are chemically identical to their branded equivalents — same active ingredient, same dosage, same quality — but sold without brand premiums. PMBI (the implementing bureau) procures medicines from government-approved manufacturers (including CPSEs and private manufacturers with Good Manufacturing Practice certification), ensuring quality parity.

  • PMBJP medicines are priced 50-80% below branded equivalents, generating enormous household savings for poor and middle-class patients.
  • The product basket covers over 2,000 medicines and 300 surgical devices — covering most common disease categories.
  • Over 18,000 JAKs are operational across all states and UTs, including in tribal, hilly, and remote areas.
  • Target: 25,000 JAKs by March 2027, ensuring one Kendra per 10,000 population in smaller towns and rural areas.
  • The scheme has contributed to cumulative estimated savings of over ₹30,000 crore for consumers (as of 2024 data).

Connection to this news: The 8th Diwas marks PMBJP's maturation from a pilot scheme to a mass-access healthcare infrastructure, with the honoring of Kendra operators recognising their role as last-mile health delivery agents, especially in areas where private pharmacies are expensive.

Generic Medicines, Price Regulation, and India's Pharmaceutical Policy

India is the world's largest supplier of generic medicines by volume, exporting to over 200 countries, but paradoxically, domestic medicine prices remain heavily brand-driven. The National Pharmaceutical Pricing Authority (NPPA), established under the DPCO (Drug Price Control Order), regulates prices of essential medicines listed in the National List of Essential Medicines (NLEM). The NLEM 2022 revision lists 384 medicines for price control. However, most non-NLEM medicines are sold at unregulated branded prices — creating the affordability gap that PMBJP addresses through direct generic sale.

  • India's pharmaceutical sector: ~₹3.5 lakh crore (domestic + exports); India supplies 20% of global generic medicines by volume.
  • NPPA controls prices of NLEM medicines through a market-based pricing (simple average) mechanism; non-NLEM medicines face only formulation-based ceiling controls.
  • Branded generics — a uniquely Indian phenomenon — are generics sold under a brand name with a premium markup, confusing the market between "branded" and "generic."
  • The Medical Council of India's (now NMC's) regulations now require doctors to prescribe by generic name (International Nonproprietary Name or INN) wherever possible — a supply-side push to drive patients toward generic outlets like JAKs.

Connection to this news: PMBJP's success depends not just on supply (Kendra numbers) but on prescription practices. The NMC directive on generic prescriptions creates a complementary demand pull toward JAKs, making the scheme's expansion to 25,000 Kendras more commercially viable.

Universal Health Coverage (UHC) and India's Healthcare Access Challenge

Universal Health Coverage — ensuring every person receives quality health services without financial hardship — is Sustainable Development Goal 3.8. India's public health expenditure remains low at approximately 2.1-2.5% of GDP (against a WHO recommendation of 5%), creating a significant out-of-pocket expenditure (OOPE) burden. India's OOPE on health is among the highest globally — approximately 48% of total health expenditure — pushing millions into poverty annually. PMBJP directly reduces OOPE on medicines, which constitute the largest single component of household health spending in India. Ayushman Bharat (PM-JAY) addresses hospitalisation costs; PMBJP addresses outpatient medicine costs — together they form India's two-pronged strategy for reducing catastrophic health expenditure.

  • SDG 3.8: Universal Health Coverage by 2030 — including access to essential medicines and vaccines.
  • India's OOPE on health: ~48% of total health expenditure — among the highest in Asia.
  • PM-JAY: ₹5 lakh annual hospitalisation coverage for 50 crore beneficiaries (secondary and tertiary care).
  • PMBJP: Reduces outpatient medicine costs by 50-80% (primary and chronic care).
  • National Health Policy 2017 target: Reduce OOPE to 25% of total health expenditure by 2025 — still not achieved, with PMBJP expansion part of the strategy.

Connection to this news: The 8th Janaushadhi Diwas' focus on awareness alongside access acknowledges that even with 18,000 Kendras, large populations are unaware of or reluctant to use generic medicines. Overcoming this awareness-trust gap is as important as expanding the Kendra network for achieving UHC goals.

Key Facts & Data

  • 8th Jan Aushadhi Diwas: March 7, 2026. Theme: "Jan Aushadhi Sasti Bhi, Bharosemand Bhi."
  • Active JAKs: 18,000+ across all states/UTs; target: 25,000 by March 31, 2027.
  • Medicine basket: 2,000+ generic medicines and 300 surgical devices.
  • Price advantage: 50-80% cheaper than branded equivalents.
  • Cumulative consumer savings: over ₹30,000 crore (as of 2024).
  • PMBJP under: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers; implemented by PMBI.
  • NLEM 2022: 384 medicines under price control by NPPA via DPCO.
  • India's OOPE on health: ~48% of total health expenditure (among highest globally).
  • India's public health expenditure: ~2.1-2.5% of GDP.